Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis (Q36623913)

15 August 2017

1 reference

title

Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis (English)

1 reference

15 August 2017

main subject

Stevens–Johnson syndrome

1 reference

Sami L Bahna

1 reference

15 August 2017

Barzin Khalili

1 reference

15 August 2017

publication date

1 September 2006

1 reference

Annals of Allergy, Asthma & Immunology

15 August 2017

published in

1 reference

15 August 2017

1 reference

15 August 2017

1 reference

15 August 2017

page(s)

272-80; quiz 281-3, 320

1 reference

Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Severe adverse cutaneous reactions to drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. Report of a patient treated with corticosteroid "pulse therapy"

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Evaluation of the potential role of cytokines in toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

A case of toxic epidermal necrolysis treated with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fas-ligand expression

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Intravenous immunoglobulin for treatment of toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Human polyspecific immunoglobulin for therapeutic use induces p21/WAF-1 and Bcl-2, which may be responsible for G1 arrest and long-term survival

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

SCORTEN: a severity-of-illness score for toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Toxic epidermal necrolysis: does immunoglobulin make a difference?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Outcome of patients with toxic epidermal necrolysis syndrome revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

The effects of cyclosporin A on the immune system

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Drug-induced toxic epidermal necrolysis treated with cyclosporin.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Toxic epidermal necrolysis treated with cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Toxic epidermal necrolysis associated with severe hypocalcaemia, and treated with cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Toxic epidermal necrolysis and cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Two unusual cases of toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Treatment of toxic epidermal necrolysis with cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960789-2

7 January 2021

10.1016/S1081-1206(10)60789-2

Identifiers

DOI

1 reference

15 August 2017

1 reference